Share

“Minimally important differences for interpreting the EORTC QLQ-C30 in advanced colorectal cancer patients treated with chemotherapy”

New QLG paper accepted by the journal “Colorectal Disease”:

“Minimally important differences for interpreting the EORTC QLQ-C30 in advanced colorectal cancer patients treated with chemotherapy”

Jammbe Z Musoro  Samantha C Sodergren  Corneel Coens  Alessia Pochesci  Mitsumi Terada  Madeleine T King  Mirjam AG Sprangers  Mogens Groenvold  Kim Cocks  Galina Velikova  Hans‐Henning Flechtner  Andrew Bottomley on behalf of the EORTC Quality of Life, Gastro‐intestinal Groups

This paper presents MIDs to aid the interpretation of EORTC QLQ-C30 change scores in patients with advanced colorectal cancer, treated with chemotherapy. This work is part of the EORTC MID project that aims to gather empirical evidence on patterns of MID estimates across EORTC QLQ-C30 scales and disease sites. Our findings support evidence that scale specific MIDs should be selected with caution.

 

Back to news list

Related News

  • New study validates clustering of QLQ-30 HRQoL scales, which can help symptom burden management and inform clinical trial design 

  • EORTC QLG Executive Committee – Call for Candidates

  • EORTC Quality of Life Group Open Access Policy

  • New QLG publication “Developing an e-learning course on the use of PRO measures in oncological practice: health care professionals’ preferences for learning content and methods”

  • “Psychometric validation of the European Organisation for Research and Treatment of Cancer–Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22)”

  • “Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors”

  • “Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial”

  • “Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients”

  • UPDATE – 17-18 September 2020 Quality of Life Group Virtual Autumn meeting